Protective effect of cytosolic phospholipase A2 inhibition against inflammation and degeneration by promoting regulatory T cells in rats with experimental autoimmune encephalomyelitis

Mediators of Inflammation

Volumn 2014, Issue , 2014, Pages

  Yang, Dan ^a   Ji, Hong Fei ^a   Zhang, Xue Mei ^a   Yue, Hui ^a   Lin, Lin ^a   Ma, Yu Yan ^a   Huang, Xiang Nan ^a   Fu, Jin ^a   Wang, Wei Zhi ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AX 059; CD4 ANTIGEN; CYTOSOLIC PHOSPHOLIPASE A2; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 6; PHOSPHOLIPASE INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; AMIDE; CYTOKINE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DEGENERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DEMYELINATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME INHIBITION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FEMALE; INFLAMMATION; LYMPHOCYTE PROLIFERATION; MONOCYTE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PROTEIN EXPRESSION; RAT; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; ANIMAL; CYTOSOL; ENZYMOLOGY; FLOW CYTOMETRY; HOMEOSTASIS; IMMUNOLOGY; LEWIS RAT; METABOLISM; TH1 CELL; TH17 CELL;

AMIDES; ANIMALS; CYTOKINES; CYTOSOL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; FLOW CYTOMETRY; HOMEOSTASIS; INFLAMMATION; PHOSPHOLIPASE A2 INHIBITORS; PHOSPHOLIPASES A2; RATS; RATS, INBRED LEW; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; TH17 CELLS;

EID: 84899472612     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2014/890139     Document Type: Article

References (41)

1. Nylander A., Hafler D. A., Multiple sclerosis. Journal of Clinical Investigation 2012 122 4 1180 1188 2-s2.0-84859724482 10.1172/JCI58649
2. Krishnamoorthy G., Wekerle H., EAE: an immunologist's magic eye. European Journal of Immunology 2009 39 8 2031 2035 2-s2.0-70249106760 10.1002/eji.200939568
3. O'Brien K., Gran B., Rostami A., T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis. Immunotherapy 2010 2 1 99 115 2-s2.0-77953427672 10.2217/imt.09.61
4. Frohman E. M., Racke M. K., Raine C. S., Medical progress: multiple sclerosis-the plaque and its pathogenesis. The New England Journal of Medicine 2006 354 9 942 955 2-s2.0-33644607018 10.1056/NEJMra052130
5. Lowther D. E., Hafler D. A., Regulatory T cells in the central nervous system. Immunological Reviews 2012 248 1 156 169
6. Buc M., Role of regulatory T cells in pathogenesis and biological therapy of multiple sclerosis. Mediators of Inflammation 2013 2013 11 963748 10.1155/2013/963748
7. Wing K., Sakaguchi S., Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nature Immunology 2010 11 1 7 13 2-s2.0-74049164847 10.1038/ni.1818
8. Venken K., Hellings N., Liblau R., Stinissen P., Disturbed regulatory T cell homeostasis in multiple sclerosis. Trends in Molecular Medicine 2010 16 2 58 68 2-s2.0-76249094369 10.1016/j.molmed.2009.12.003
9. + regulatory cells mediate genetic resistance to experimental autoimmune encephalomyelitis. Proceedings of the National Academy of Sciences of the United States of America 2004 101 43 15434 15439 2-s2.0-7444250675 10.1073/pnas.0404444101 (Pubitemid 39441559)
10. Korn T., Bettelli E., Gao W., Awasthi A., Jäger A., Strom T. B., Oukka M., Kuchroo V. K., IL-21 initiates an alternative pathway to induce proinflammatory T H17 cells. Nature 2007 448 7152 484 487 2-s2.0-34547232503 10.1038/nature05970 (Pubitemid 47123515)
11. Liu Y., Teige I., Birnir B., Issazadeh-Navikas S., Neuron-mediated generation of regulatory T cells from encephalitogenic T cells suppresses EAE. Nature Medicine 2006 12 5 518 525 2-s2.0-33646596928 10.1038/nm1402
12. Burke J. E., Dennis E. A., Phospholipase A2 structure/function, mechanism, and signaling. Journal of Lipid Research 2009 50, supplement S237 S242
13. Magrioti V., Kokotos G., Phospholipase A2 inhibitors for the treatment of inflammatory diseases: a patent review (2010-present). Expert Opinion on Therapeutic Patents 2013 23 3 333 344
14. Dennis E. A., Cao J., Hsu Y.-H., Magrioti V., Kokotos G., Phospholipase A2 enzymes: physical structure, biological function, disease implication, chemical inhibition, and therapeutic intervention. Chemical Reviews 2011 111 10 6130 6185 2-s2.0-80054082654 10.1021/cr200085w
15. Kalyvas A., David S., s Cytosolic phospholipase A2 plays a key role in the pathogenesis of multiple sclerosis-like disease. Neuron 2004 41 3 323 335 2-s2.0-1242293632 10.1016/S0896-6273(04)00003-0 (Pubitemid 38221038)
16. Payne S. G., Oskeritzian C. A., Griffiths R., Subramanian P., Barbour S. E., Chalfant C. E., Milstien S., Spiegel S., The immunosuppressant drug FTY720 inhibits cytosolic phospholipase A2 independently of sphingosine-1-phosphate receptors. Blood 2007 109 3 1077 1085 2-s2.0-33846864904 10.1182/blood-2006-03- 011437 (Pubitemid 46220654)
17. Marusic S., Thakker P., Pelker J. W., Stedman N. L., Lee K. L., McKew J. C., Han L., Xu X., Wolf S. F., Borey A. J., Cui J., Shen M. W. H., Donahue F., Hassan-Zahraee M., Leach M. W., Shimizu T., Clark J. D., Blockade of cytosolic phospholipase A2 α prevents experimental autoimmune encephalomyelitis and diminishes development of Th1 and Th17 responses. Journal of Neuroimmunology 2008 204 1-2 29 37 2-s2.0-54349089792 10.1016/j.jneuroim.2008.08.012
18. Mannie M., Swanborg R. H., Stepaniak J. A., Experimental autoimmune encephalomyelitis in the rat. Current Protocols in Immunology 2009 85 15 589 612 2-s2.0-64249124550 10.1002/0471142735.im1502s85
19. Stephens D., Barbayianni E., Constantinou-Kokotou V., Peristeraki A., Six D. A., Cooper J., Harkewicz R., Deems R. A., Dennis E. A., Kokotos G., Differential inhibition of group IVA and group VIA phospholipases A 2 by 2-oxoamides. Journal of Medicinal Chemistry 2006 49 9 2821 2828 2-s2.0-33646461525 10.1021/jm050993h
20. Barbayianni E., Stephens D., Grkovich A., Magrioti V., Hsu Y.-H., Dolatzas P., Kalogiannidis D., Dennis E. A., Kokotos G., 2-Oxoamide inhibitors of phospholipase A2 activity and cellular arachidonate release based on dipeptides and pseudodipeptides. Bioorganic and Medicinal Chemistry 2009 17 13 4833 4843 2-s2.0-66449102111 10.1016/j.bmc.2009.03.069
21. Farooqui A. A., Ong W.-Y., Horrocks L. A., Inhibitors of brain phospholipase A2 activity: their neuropharmacological effects and therapeutic importance for the treatment of neurologic disorders. Pharmacological Reviews 2006 58 3 591 620 2-s2.0-33748804968 10.1124/pr.58.3.7 (Pubitemid 44403685)
22. Kalyvas A., Baskakis C., Magrioti V., Constantinou-Kokotou V., Stephens D., Lpez-Vales R., Lu J.-Q., Yong V. W., Dennis E. A., Kokotos G., David S., Differing roles for members of the phospholipase A2 superfamily in experimental autoimmune encephalomyelitis. Brain 2009 132 5 1221 1235 2-s2.0-66549114353 10.1093/brain/awp002
23. Nomura D. K., Morrison B. E., Blankman J. L., Long J. Z., Kinsey S. G., Marcondes M. C. G., Ward A. M., Hahn Y. K., Lichtman A. H., Conti B., Cravatt B. F., Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011 334 6057 809 813 2-s2.0-81055156684 10.1126/science.1209200
24. Marusic S., Leach M. W., Pelker J. W., Azoitei M. L., Uozumi N., Cui J., Shen M. W. H., DeClercq C. M., Miyashiro J. S., Carito B. A., Thakker P., Simmons D. L., Leonard J. P., Shimizu T., Clark J. D., Cytosolic phospholipase A2 α -deficient mice are resistant to experimental autoimmune encephalomyelitis. Journal of Experimental Medicine 2005 202 6 841 851 2-s2.0-25144519259 10.1084/jem.20050665 (Pubitemid 41345972)
25. Sundaram J. R., Chan E. S., Poore C. P., Pareek T. K., Cheong W. F., Shui G., Tang N., Low C.-M., Wenk M. R., Kesavapany S., Cdk5/p25-induced cytosolic PLA2-mediated lysophosphatidylcholine production regulates neuroinflammation and triggers neurodegeneration. Journal of Neuroscience 2012 32 3 1020 1034 2-s2.0-84856007240 10.1523/JNEUROSCI.5177-11.2012
26. Thakker P., Marusic S., Stedman N. L., Lee K. L., McKew J. C., Wood A., Goldman S. J., Leach M. W., Collins M., Kuchroo V. K., Wolf S. F., Clark J. D., Hassan-Zahraee M., Cytosolic phospholipase A2 α blockade abrogates disease during the tissue-damage effector phase of experimental autoimmune encephalomyelitis by its action on APCs. Journal of Immunology 2011 187 4 1986 1997 2-s2.0-80051949664 10.4049/jimmunol.1002789
27. Taketomi Y., Ueno N., Kojima T., Mast cell maturation is driven via a group III phospholipase A2-prostaglandin D2-DP1 receptor paracrine axis. Nature Immunology 2013 14 6 554 563
28. Bodhankar S., Vandenbark A. A., Offner H., Oestrogen treatment of experimental autoimmune encephalomyelitis requires 17 β-oestradiol- receptor-positive B cells that up-regulate PD-1 on CD4+ Foxp3+ regulatory T cells. Immunology 2012 137 4 282 293
29. Morales-Tirado V., Wichlan D. G., Leimig T. E., Street S. E. A., Kasow K. A., Riberdy J. M., 1 α25-dihydroxyvitamin D3 (vitamin D3) catalyzes suppressive activity on human natural regulatory T cells, uniquely modulates cell cycle progression, and augments FOXP3. Clinical Immunology 2011 138 2 212 221 2-s2.0-79251595352 10.1016/j.clim.2010.11.003
30. Rouse M., Nagarkatti M., Nagarkatti P. S., The role of IL-2 in the activation and expansion of regulatory T-cells and the development of experimental autoimmune encephalomyelitis. Immunobiology 2013 218 4 674 682
31. Dimeloe S., Nanzer A., Ryanna K., Hawrylowicz C., Regulatory T cells, inflammation and the allergic response-The role of glucocorticoids and Vitamin D. Journal of Steroid Biochemistry and Molecular Biology 2010 120 2-3 86 95 2-s2.0-77952953783 10.1016/j.jsbmb.2010.02.029
32. Dhib-Jalbut S., Marks S., Interferon- β mechanisms of action in multiple sclerosis. Neurology 2010 74 S17 S24 2-s2.0-74249112995 10.1212/WNL.0b013e3181c97d99
33. Racke M. K., Lovett-Racke A. E., Glatiramer acetate treatment of multiple sclerosis: an immunological perspective. Journal of Immunology 2011 186 4 1887 1890 2-s2.0-79951818195 10.4049/jimmunol.1090138
34. Barnaba V., Schinzari V., Induction, control, and plasticity of Treg cells: the immune regulatory network revised? European Journal of Immunology 2013 43 2 318 322
35. Samanta A., Li B., Song X., Bembas K., Zhang G., Katsumata M., Saouaf S. J., Wang Q., Hancock W. W., Shen Y., Greene M. I., TGF- β and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3. Proceedings of the National Academy of Sciences of the United States of America 2008 105 37 14023 14027 2-s2.0-52949138267 10.1073/pnas.0806726105
36. Kimura A., Kishimoto T., IL-6: regulator of Treg/Th17 balance. European Journal of Immunology 2010 40 7 1830 1835 2-s2.0-77954096689 10.1002/eji.201040391
37. Bettelli E., Carrier Y., Gao W., Korn T., Strom T. B., Oukka M., Weiner H. L., Kuchroo V. K., Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 441 7090 235 238 2-s2.0-33646577466 10.1038/nature04753
38. Goodman W. A., Levine A. D., Massari J. V., IL-6 signaling in psoriasis prevents immune suppression by regulatory T cells. Journal of Immunology 2009 183 5 3170 3176
39. Goodman W. A., Young A. B., McCormick T. S., Cooper K. D., Levine A. D., Stat3 phosphorylation mediates resistance of primary human T cells to regulatory T cell suppression. Journal of Immunology 2011 186 6 3336 3345 2-s2.0-79953172216 10.4049/jimmunol.1001455
40. Murai M., Turovskaya O., Kim G., Madan R., Karp C. L., Cheroutre H., Kronenberg M., Interleukin 10 acts on regulatory T cells to maintain expression of the transcription factor Foxp3 and suppressive function in mice with colitis. Nature Immunology 2009 10 11 1178 1184 2-s2.0-70350464351 10.1038/ni.1791
41. Klose J., Schmidt N. O., Melms A., Suppression of experimental autoimmune encephalomyelitis by interleukin-10 transduced neural stem/progenitor cells. Journal of Neuroinflammation 2013 10 1 117